Journal
SEMINARS IN IMMUNOLOGY
Volume 22, Issue 3, Pages 155-161Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2010.04.007
Keywords
Cancer vaccines; Adjuvants; Innate immunity; TLR-4 agonists; Cancer immunotherapy; TLR ligands; Emulsions; Cytotoxic T cells
Categories
Ask authors/readers for more resources
The recent FDA approval of sipuleucel-T (Provenge (R)), a patient-specific immunotherapy for androgen-independent prostate cancer developed by Dendreon Corporation, has provided support for the concept of cellular immunotherapy as an approach to cancer treatment. Adjuvants are compounds that enhance the potency of the antigen-specific immune response and can be an essential component of an efficacious vaccine. Cervarix is a prophylactic vaccine against human papilloma virus (HPV) types 16 and 18, which can cause cervical cancer, and recently received approval from the FDA, due in part to the protective immunity it conferred against not only HPV types contained in the vaccine but in addition to oncogenic HPV strains that were not contained in the vaccine. Cervarix (R) is formulated with MPL (monophosphoryl lipid A), a TLR-4 targeted adjuvant shown to promote immune response broadening. The recent FDA approvals of these pioneering vaccines are landmark events, and will likely usher in renewed interest and investment in the development of new therapeutic cancer vaccine candidates. In this review, we examine new molecularly defined adjuvants and formulations and its application to cancer vaccines under development. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available